Angiogenesis in cutaneous lesions of leprosy: Implications for treatment

Archives of Dermatology

Volumn 143, Issue 12, 2007, Pages 1527-1529

  Bhandarkar, Sulochana S ^a,c   Cohen, Cynthia ^a   Kuruvila, Maria ^c   Rea, Thomas H ^d   MacKelfresh, Jamie B ^a   Lee, Delphine J ^b   Modlin, Robert L ^b   Arbiser, Jack L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KASTURBA MEDICAL COLLEGE   (India)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN;

ANGIOGENESIS; ARTICLE; BACTERIAL COUNT; BORDERLINE LEPROSY; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEPROMATOUS LEPROSY; LEPROSY; MICROVASCULATURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SKIN BLOOD VESSEL; SKIN DEFECT; TUBERCULOID LEPROSY;

ANGIOGENESIS INHIBITORS; ANTIGENS, CD31; BLOOD VESSELS; HUMANS; IMMUNOHISTOCHEMISTRY; LEPROSY; LEPROSY, BORDERLINE; LEPROSY, LEPROMATOUS; LEPROSY, TUBERCULOID; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; SKIN;

EID: 37249041613     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.12.1527     Document Type: Article

References (25)

1. Padma TV. With scores still infected, India declares leprosy "eliminated." Nat Med. 2006;12(4):372.
2. Deps PD, Guedes BV, Bucker Filho J, Andreatta MK, Marcari RS, Rodrigues LC. Characteristics of known leprosy contact in a high endemic area in Brazil. Lepr Rev. 2006;77(1):34-40.
3. Williams MC. How can adherence with multi-drug therapy in leprosy be improved? Lepr Rev. 2005;76(2):160-161.
4. Ustianowski AP, Lawn SD, Lockwood DN. Interactions between HIV infection and leprosy: a paradox. Lancet Infect Dis. 2006;6(6):350-360.
5. Cross H. Interventions to address the stigma associated with leprosy: a perspective on the issues. Psychol Health Med. 2006;11(3):367-373.
6. Ridley DS, Jopling WH. A classification of leprosy for research purposes. Lepr Rev. 1962;33:119-128.
7. Ridley DS, Jopling WH. Classification of leprosy according to immunity - a five-group system. Int J Lepr Other Mycobact Dis. 1966;34(3):255-273.
8. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995;87(8):581-586.
9. Kim J, Uyemura K, Van Dyke MK, et al. A role for IL-12 receptor expression and signal transduction in host defense in leprosy. J Immunol. 2001;167(2):779-786.
10. Libraty DH, Airan LE, Uyemura K, et al. Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy. J Clin Invest. 1997;99(2):336-341.
11. Ueno T, Toi M, Saji H, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000;6(8):3282-3289.
12. Drexler HG, Uphoff CC, Gaidano G, Carbone A. Lymphoma cell lines: in vitro models for the study of HHV-8 primary effusion lymphomas (body cavity-based lymphomas). Leukemia. 1998;12(10):1507-1517.
13. Hatanaka H, Abe Y, Naruke M, et al. Significant correlation between interleukin 10 expression and vascularization through angiopoietin/TIE2 networks in non-small cell lung cancer. Clin Cancer Res. 2001;7(5):1287-1292.
14. Arbiser JL, Johnson D, Cohen C, Brown LF. High-level expression of vascular endothelial growth factor and its receptors in an aphthous ulcer. J Cutan Med Surg. 2003;7(3):225-228.
15. Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Res. 1991;51(2):672-675.
16. Arbiser JL, Flynn E, Barnhill RL. Analysis of vascularity of human neurofibromas. J Am Acad Dermatol. 1998;38(6, pt 1):950-954.
17. Arbiser JL, Brat D, Hunter S, et al. Tuberous sclerosis-associated lesions of the kidney, brain and skin are angiogenic neoplasms. J Am Acad Dermatol. 2002;46(3):376-380.
18. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992;84(24):1875-1887.
19. Macaron NC, Cohen C, Chen SC, Arbiser JL. Cutaneous lesions of secondary syphilis are highly angiogenic. J Am Acad Dermatol. 2003;48(6):878-881.
20. Rambukkana A, Yamada H, Zanazzi G, et al. Role of alpha-dystroglycan as a Schwann cell receptor for Mycobacterium leprae. Science. 1998;282(5396):2076-2079.
21. Britton WJ, Lockwood DN. Leprosy [review]. Lancet. 2004;363(9416):1209-1219.
22. Findlay GH. Indeterminate leprosy: a new clinical variety. Br J Dermatol. 1951;63 (3):100-104.
23. Yawalkar SJ. Leprosy: For Medical Practitioners and Paramedical Workers. 7th ed. Basel, Switzerland: Novartis Foundation for Sustainable Development; 2002.
24. Mira MT. Genetic host resistance and susceptibility to leprosy. Microbes Infect. 2006;8(4):1124-1131.
25. Antunes SL, Motta E, de Almeida SM, Gallo ME, Nery JA, Lenzi HL. Distinct patterns of microvasculature in the cutaneous lesions of leprosy. Int J Lepr Other Mycobact Dis. 2000;68(2):143-151.